Literature DB >> 18722016

SATB1 is required for CD8 coreceptor reversal.

Hui Nie1, Xin Yao, Shanna D Maika, Philip W Tucker.   

Abstract

Intrathymic signals induce the differentiation of immature CD4(+)CD8(+) double positive (DP) thymocytes into mature CD4(+) or CD8(+) single positive (SP) T cells. The transcriptional mechanism by which CD8 lineage is determined is not fully understood. The best evidence, which favors the kinetic signaling/coreceptor reversal model, indicates that signaled DP thymocytes terminate CD8 transcription prior to their subsequent re-initiation of CD8 transcription and ultimate differentiation into CD8SP T cells. We and others have shown that CD8 lineage commitment is severely perturbed in mice in which expression of the transcription factor SATB1 is either conventionally knocked out or T cell-specifically knocked down. Here, we demonstrate that, as with normal thymocytes, cultured SATB1-deficient DP thymocytes inactivate CD8 coreceptor transcription following receipt of signals (PMA plus ionomycin) that mimic TCR-mediated positive selection. However, this terminated CD8 transcription is not re-initiated by signals (IL-7) conducive to CD8 differentiation in SATB1-deficient DP. We show that SATB1 specifically binds to a cis-regulatory element within the CD8 enhancer (E8(III)) known to be required for coreceptor reversal. A requirement in CD8 coreceptor reversal identifies SATB1 as an essential trans-regulator of CD8 lineage fate, whose action may be mediated via recruitment to the E8(III) DP enhancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18722016      PMCID: PMC5697725          DOI: 10.1016/j.molimm.2008.07.007

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  25 in total

1.  Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes.

Authors:  Tian H Chi; Mimi Wan; Keji Zhao; Ichiro Taniuchi; Lei Chen; Dan R Littman; Gerald R Crabtree
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

2.  The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development.

Authors:  J D Alvarez; D H Yasui; H Niida; T Joh; D Y Loh; T Kohwi-Shigematsu
Journal:  Genes Dev       Date:  2000-03-01       Impact factor: 11.361

3.  Solution structure and DNA-binding mode of the matrix attachment region-binding domain of the transcription factor SATB1 that regulates the T-cell maturation.

Authors:  Hiroshi Yamaguchi; Masaru Tateno; Kazuhiko Yamasaki
Journal:  J Biol Chem       Date:  2005-12-21       Impact factor: 5.157

4.  A role for SATB1, a nuclear matrix association region-binding protein, in the development of CD8SP thymocytes and peripheral T lymphocytes.

Authors:  Hui Nie; Shanna D Maika; Philip W Tucker; Paul D Gottlieb
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

5.  Ikaros sets thresholds for T cell activation and regulates chromosome propagation.

Authors:  N Avitahl; S Winandy; C Friedrich; B Jones; Y Ge; K Georgopoulos
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

6.  Nuclear matrix binding regulates SATB1-mediated transcriptional repression.

Authors:  Jin Seo; Mary M Lozano; Jaquelin P Dudley
Journal:  J Biol Chem       Date:  2005-04-25       Impact factor: 5.157

7.  A CD8 genomic fragment that directs subset-specific expression of CD8 in transgenic mice.

Authors:  A Hostert; M Tolaini; R Festenstein; L McNeill; B Malissen; O Williams; R Zamoyska; D Kioussis
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

8.  Tissue-specific nuclear architecture and gene expression regulated by SATB1.

Authors:  Shutao Cai; Hye-Jung Han; Terumi Kohwi-Shigematsu
Journal:  Nat Genet       Date:  2003-05       Impact factor: 38.330

9.  Negative regulation of CD8 expression via Cd8 enhancer-mediated recruitment of the zinc finger protein MAZR.

Authors:  Ivan Bilic; Christina Koesters; Bernd Unger; Masayuki Sekimata; Arnulf Hertweck; Romana Maschek; Christopher B Wilson; Wilfried Ellmeier
Journal:  Nat Immunol       Date:  2006-02-19       Impact factor: 25.606

10.  The genomic sequences bound to special AT-rich sequence-binding protein 1 (SATB1) in vivo in Jurkat T cells are tightly associated with the nuclear matrix at the bases of the chromatin loops.

Authors:  I de Belle; S Cai; T Kohwi-Shigematsu
Journal:  J Cell Biol       Date:  1998-04-20       Impact factor: 10.539

View more
  6 in total

1.  Inhibition of SATB1 by shRNA suppresses the proliferation of cutaneous malignant melanoma.

Authors:  Lei Zhang; Fang Cheng; Runzhi He; Hao Chen; Yi Liu; Jianfang Sun
Journal:  Cancer Biother Radiopharm       Date:  2014-01-07       Impact factor: 3.099

2.  The L2a element is a mouse CD8 silencer that interacts with MAR-binding proteins SATB1 and CDP.

Authors:  Xin Yao; Hui Nie; Ingrid C Rojas; June V Harriss; Shanna D Maika; Paul D Gottlieb; Gary Rathbun; Philip W Tucker
Journal:  Mol Immunol       Date:  2010-09-29       Impact factor: 4.407

Review 3.  Transcriptional control of CD4 and CD8 coreceptor expression during T cell development.

Authors:  Wilfried Ellmeier; Lena Haust; Roland Tschismarov
Journal:  Cell Mol Life Sci       Date:  2013-06-21       Impact factor: 9.261

4.  The mRNA expression of SATB1 and SATB2 in human breast cancer.

Authors:  Neill Patani; Wen Jiang; Robert Mansel; Robert Newbold; Kefah Mokbel
Journal:  Cancer Cell Int       Date:  2009-07-30       Impact factor: 5.722

5.  SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo.

Authors:  Jie Zhang; Baogang Zhang; Xumei Zhang; Yingui Sun; Xiaolong Wei; Michael A McNutt; Shijun Lu; Yuqing Liu; Donghong Zhang; Mingyu Wang; Zhijuan Lin; Na Niu
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

6.  Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells.

Authors:  Bo Huang; Hongli Zhou; Xiaodong Wang; Zhiliang Liu
Journal:  Cancer Cell Int       Date:  2013-02-05       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.